Demant A/S: Closing of divestment of cochlear implants business
Investor News 21 May 2024
Closing of the divestment of our cochlear implants business
Today, Demant announces that all regulatory approvals and customary closing conditions regarding the divestment of our cochlear implants business to Cochlear have been fulfilled and that the proposed transaction has closed effective 21 May 2024. This is in line with expectations, and in the transition period, we will work closely together with Cochlear to ensure a smooth and proper transition so they can continue to service the existing cochlear implants patients.
Following the closing of the divestment, we still expect profit after tax related to Hearing Implants to be around DKK 0 million for 2024. Our bone anchored hearing systems business (BAHS) remains with the Group for now, pending a review of strategic options.
|
Further information: Søren Nielsen, President & CEO Phone +45 3917 7300 |
Other contacts: René Schneider, CFO Peter Pudselykke, Head of Investor Relations Henrik Axel Lynge Buchter, Manager of External Communications |
Contacts
Henrik Axel Lynge Buchter
External Communication Manager
Corporate Communication & Sustainability
Tel:
About Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Alternative languages
Attachments
Subscribe to our company announcements
Keep up to date with our company announcements by subscribing.
Visit our pressroom and see more company announcements from us.
Our pressroom